Literature DB >> 12587849

Effect of loxapine on peripheral dopamine-like and serotonin receptors in patients with schizophrenia.

Amarendra N Singh1, Cia Barlas, Huma Saeedi, Ram K Mishra.   

Abstract

OBJECTIVE: To investigate the effect of loxapine on peripheral dopamine D2-like and serotonin receptor binding and on psychotic symptoms. PATIENTS: Patients (n = 24) meeting the diagnostic criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, for schizophrenia were selected from an outpatient clinic (age range 18-70 yr).
METHODS: Patients were given loxapine (dose determined by a physician) for a period of 12 weeks. There were clinic visits at before treatment began and at 6 weeks and 12 weeks of treatment. Scores on a variety of efficacy and safety scales were recorded at each visit, and blood was drawn for receptor assays.
RESULTS: Patients showed significant improvement on most psychiatric assessment scales after 6 and 12 weeks of treatment with loxapine, and both lymphocyte D2-like and 5-HTL2A platelet receptor binding were down-regulated after 6 and 12 weeks. The degree of receptor down-regulation was not significantly correlated with improvements in psychotic symptoms, however.
CONCLUSION: Loxapine down-regulated both lymphocyte D2-like and platelet 5-HT2A receptors to the same extent, suggesting that both receptors are involved in the mechanism of action of loxapine in patients with schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12587849      PMCID: PMC161724     

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN: 1180-4882            Impact factor:   6.186


  44 in total

Review 1.  Does loxapine have "atypical" properties? Clinical evidence.

Authors:  W M Glazer
Journal:  J Clin Psychiatry       Date:  1999       Impact factor: 4.384

Review 2.  Neuroanatomical, neuropharmacological and neurobiochemical target systems for antipsychotic activity of neuroleptics.

Authors:  A Delini-Stula
Journal:  Pharmacopsychiatry       Date:  1986-07       Impact factor: 5.788

Review 3.  Dopamine receptor pharmacology.

Authors:  P Seeman; H H Van Tol
Journal:  Trends Pharmacol Sci       Date:  1994-07       Impact factor: 14.819

4.  Decrease in lymphocyte [3H]spiroperidol binding sites in Parkinsonism.

Authors:  G Le Fur; V Meininger; T Phan; A Gérard; M Baulac; A Uzan
Journal:  Life Sci       Date:  1980-10-27       Impact factor: 5.037

5.  Dopamine D1-like receptor subtypes in human peripheral blood lymphocytes.

Authors:  A Ricci; E Bronzetti; F Mignini; S K Tayebati; D Zaccheo; F Amenta
Journal:  J Neuroimmunol       Date:  1999-05-03       Impact factor: 3.478

6.  PET evidence that loxapine is an equipotent blocker of 5-HT2 and D2 receptors: implications for the therapeutics of schizophrenia.

Authors:  S Kapur; R Zipursky; G Remington; C Jones; G McKay; S Houle
Journal:  Am J Psychiatry       Date:  1997-11       Impact factor: 18.112

7.  Dopamine D2-like receptors on human peripheral blood lymphocytes: a radioligand binding assay and immunocytochemical study.

Authors:  F Amenta; E Bronzetti; L Felici; A Ricci; S K Tayebati
Journal:  J Auton Pharmacol       Date:  1999-06

8.  Platelet serotonergic indices in major depression: up-regulation of 5-HT2A receptors unchanged by antidepressant treatment.

Authors:  P D Hrdina; D Bakish; A Ravindran; J Chudzik; P Cavazzoni; Y D Lapierre
Journal:  Psychiatry Res       Date:  1997-02-07       Impact factor: 3.222

Review 9.  Pharmacologic features and effects of neuroleptics.

Authors:  M V Seeman
Journal:  Can Med Assoc J       Date:  1981-10-15       Impact factor: 8.262

10.  Catecholamines and their receptors in blood: evidence for alterations in schizophrenia.

Authors:  B Bondy; M Ackenheil; W Birzle; R Elbers; M Fröhler
Journal:  Biol Psychiatry       Date:  1984-10       Impact factor: 13.382

View more
  5 in total

Review 1.  Biomarkers in schizophrenia: A focus on blood based diagnostics and theranostics.

Authors:  Chi-Yu Lai; Elizabeth Scarr; Madhara Udawela; Ian Everall; Wei J Chen; Brian Dean
Journal:  World J Psychiatry       Date:  2016-03-22

Review 2.  Loxapine inhalation powder: a review of its use in the acute treatment of agitation in patients with bipolar disorder or schizophrenia.

Authors:  Gillian M Keating
Journal:  CNS Drugs       Date:  2013-06       Impact factor: 5.749

3.  The dopaminergic system in peripheral blood lymphocytes: from physiology to pharmacology and potential applications to neuropsychiatric disorders.

Authors:  Francesca R Buttarelli; Alessandra Fanciulli; Clelia Pellicano; Francesco E Pontieri
Journal:  Curr Neuropharmacol       Date:  2011-06       Impact factor: 7.363

Review 4.  Pharmacological Interventions for the MATRICS Cognitive Domains in Schizophrenia: What's the Evidence?

Authors:  Wilhelmina A M Vingerhoets; Oswald J N Bloemen; Geor Bakker; Therese A M J van Amelsvoort
Journal:  Front Psychiatry       Date:  2013-12-04       Impact factor: 4.157

Review 5.  Theranostic Biomarkers for Schizophrenia.

Authors:  Matea Nikolac Perkovic; Gordana Nedic Erjavec; Dubravka Svob Strac; Suzana Uzun; Oliver Kozumplik; Nela Pivac
Journal:  Int J Mol Sci       Date:  2017-03-30       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.